<div id="readability-page-1"><div>By Connor Hart Genentech, a member of the Roche Group, said the U.S. Food and Drug Administration approved its treatment for follicular lymphoma. The therapy, Lunsumio VELO, can be used to treat adult patients with relapsed or refractory follicular lymphoma, a type of cancer of the lymphatic system, following two or more lines of systemic therapy, the company said Monday. Lunsumio VELO reduces administration time with an approximately one-minute injection, compared with an intravenous infusion of up to four hours, according to Genentech. &#34;With this FDA approval, treatment can now be administered in just one minute, which significantly reduces the time patients spend in the clinic and helps to align care with their individual needs and preferences,&#34; Levi Garraway, chief medical officer and head of global product development, said. Lunsumio VELO's approval is based on the primary analysis of a recent study, in which patients receiving the treatment showed a 75% objective response rate and a 59% complete response rate, Genentech said. Write to Connor Hart at connor.hart@wsj.com (END) Dow Jones Newswires12-22-25 0739ET</div></div>

RHHBY

Genentech, part of the Roche Group, has received FDA approval for Lunsumio VELO, a treatment for relapsed or refractory follicular lymphoma. This therapy offers a significant reduction in administration time, requiring only a one-minute injection compared to a four-hour infusion. The approval is based on a study showing a 75% objective response rate and a 59% complete response rate. This advancement aligns with patient needs for more efficient treatment options.

Genentech Receives FDA Approval for Lymphoma Treatment